ClinicalTrials.gg
TerminatedNCT00286169Updated Apr 12, 2022

Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC)

A Phase 3 interventional study of Amrubicin Hydrochloride in Small-cell Lung Cancer, sponsored by Sumitomo Pharma Co., Ltd.. Terminated at 8 sites in Japan. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2022-04-12.

Sponsored by Sumitomo Pharma Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
70 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 78 studies in Small Cell Lung Carcinoma with a site in Japan — 27 open to participants now, 44 under way, 18 of them phase 3. Small Cell Lung Carcinoma · Japan.

Planned enrollment
53rd of 76
130 · median 240
Started
2006
the only one that year
Phase 3
26 of 78
9 open now
Registered
3rd of 78
by date

Among the 78 studies in Small Cell Lung Carcinoma with a site in Japan, this one is the 53rd largest by planned enrollment of the 76 interventional ones that give a count, is the only one that started in 2006, is one of 26 in phase 3, and was the 3rd registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

27 of the 78 studies in Small Cell Lung Carcinoma with a site in Japan are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 70 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Small Cell Lung Carcinoma with a site in Japan, or all of them as a file.
02

Study summary

The purpose of this study is to compare the efficacy and toxicity of amrubicin with carboplatin plus etoposide in elderly patients with extensive-disease small-cell lung cancer.

03

Conditions studied

  • Small-cell Lung Cancer

Keywords

  • Extensive-disease small-cell lung cancer (ED-SCLC)
04

Who can participate

Ages eligible
70 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Extensive-disease small-cell lung cancer
  • Aged 70 years or older
  • Performance status of 0-2
  • No prior chemotherapy

Exclusion criteria

Exclusion Criteria:

  • Prior therapy for primary lesion
  • Pneumonitis and/or pulmonary fibrosis
  • Active concomitant
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
130 participants (estimated)

Interventions

06

What researchers measure

Primary outcomes

  1. Overall survival

Secondary outcomes

  1. Time to progression

  2. Objective tumor response

  3. Quality of Life (QOL: EuroQOL, FACT-L-LCS)

  4. Frequency and severity of adverse events

07

Study locations

8 sites
  • Chubu Region Site
    Chubu, Japan
  • Chugoku Region Site
    Chugoku, Japan
  • Hokkaido Region Site
    Hokkaido, Japan
  • Kanto Region Site
    Kanto, Japan
  • Kinki Region Site
    Kinki, Japan
  • Kyushu Region Site
    Kyushu, Japan
  • Shikoku Region Site
    Shikoku, Japan
  • Tohoku Region Site
    Tohoku, Japan
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00286169
First posted
Feb 3, 2006
Start date
Apr 2006
Last update
Apr 12, 2022

Study contacts

Drug Development Division
study director · Sumitomo Pharma Co., Ltd.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amrubicin

Start the discussion